nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—CHRND—pericardium—esophageal cancer	0.0879	0.291	CbGeAlD
Galantamine—BCHE—diaphragm—esophageal cancer	0.0403	0.133	CbGeAlD
Galantamine—CHRNG—trachea—esophageal cancer	0.0156	0.0517	CbGeAlD
Galantamine—CHRNG—lung—esophageal cancer	0.0112	0.0371	CbGeAlD
Galantamine—CHRNA5—lymph node—esophageal cancer	0.0107	0.0355	CbGeAlD
Galantamine—Atrial arrhythmia—Capecitabine—esophageal cancer	0.0107	0.0262	CcSEcCtD
Galantamine—Infarction—Capecitabine—esophageal cancer	0.0107	0.0262	CcSEcCtD
Galantamine—CHRNB2—bronchus—esophageal cancer	0.0106	0.035	CbGeAlD
Galantamine—CHRNB2—smooth muscle tissue—esophageal cancer	0.0104	0.0343	CbGeAlD
Galantamine—CHRNA7—neck—esophageal cancer	0.01	0.0331	CbGeAlD
Galantamine—CHRNB2—trachea—esophageal cancer	0.00951	0.0315	CbGeAlD
Galantamine—CHRND—lung—esophageal cancer	0.00889	0.0294	CbGeAlD
Galantamine—Cognitive impairment—Methotrexate—esophageal cancer	0.00845	0.0208	CcSEcCtD
Galantamine—Arrhythmia supraventricular—Capecitabine—esophageal cancer	0.00764	0.0188	CcSEcCtD
Galantamine—CHRFAM7A—trachea—esophageal cancer	0.00746	0.0247	CbGeAlD
Galantamine—CHRNB2—lung—esophageal cancer	0.00683	0.0226	CbGeAlD
Galantamine—CHRNA3—lung—esophageal cancer	0.00662	0.0219	CbGeAlD
Galantamine—CHRNA4—bronchus—esophageal cancer	0.00662	0.0219	CbGeAlD
Galantamine—CHRNA10—lymph node—esophageal cancer	0.0065	0.0215	CbGeAlD
Galantamine—Disorder sight—Capecitabine—esophageal cancer	0.00622	0.0153	CcSEcCtD
Galantamine—Transient ischaemic attack—Capecitabine—esophageal cancer	0.00587	0.0144	CcSEcCtD
Galantamine—CHRNA7—digestive system—esophageal cancer	0.00518	0.0172	CbGeAlD
Galantamine—CHRNA4—digestive system—esophageal cancer	0.00511	0.0169	CbGeAlD
Galantamine—Cognitive disorder—Methotrexate—esophageal cancer	0.0051	0.0125	CcSEcCtD
Galantamine—CHRNB2—lymph node—esophageal cancer	0.00467	0.0155	CbGeAlD
Galantamine—Aphasia—Capecitabine—esophageal cancer	0.00457	0.0112	CcSEcCtD
Galantamine—CHRNA3—lymph node—esophageal cancer	0.00453	0.015	CbGeAlD
Galantamine—Supraventricular tachycardia—Capecitabine—esophageal cancer	0.00452	0.0111	CcSEcCtD
Galantamine—CHRNA4—lung—esophageal cancer	0.00427	0.0141	CbGeAlD
Galantamine—Hiccups—Cisplatin—esophageal cancer	0.00402	0.00988	CcSEcCtD
Galantamine—CHRNB1—lymph node—esophageal cancer	0.00392	0.013	CbGeAlD
Galantamine—Body temperature increased—Carboplatin—esophageal cancer	0.00386	0.0095	CcSEcCtD
Galantamine—Coagulopathy—Capecitabine—esophageal cancer	0.0038	0.00936	CcSEcCtD
Galantamine—BCHE—bronchus—esophageal cancer	0.00378	0.0125	CbGeAlD
Galantamine—BCHE—smooth muscle tissue—esophageal cancer	0.0037	0.0123	CbGeAlD
Galantamine—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00368	0.00906	CcSEcCtD
Galantamine—Aphasia—Methotrexate—esophageal cancer	0.0034	0.00836	CcSEcCtD
Galantamine—BCHE—trachea—esophageal cancer	0.0034	0.0113	CbGeAlD
Galantamine—ACHE—lymph node—esophageal cancer	0.0034	0.0112	CbGeAlD
Galantamine—Rectal haemorrhage—Capecitabine—esophageal cancer	0.00328	0.00806	CcSEcCtD
Galantamine—Nocturia—Capecitabine—esophageal cancer	0.00319	0.00785	CcSEcCtD
Galantamine—Cataract—Capecitabine—esophageal cancer	0.00311	0.00765	CcSEcCtD
Galantamine—Bone pain—Capecitabine—esophageal cancer	0.00309	0.0076	CcSEcCtD
Galantamine—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00298	0.00732	CcSEcCtD
Galantamine—Hiccups—Capecitabine—esophageal cancer	0.00296	0.00728	CcSEcCtD
Galantamine—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.00296	0.00728	CcSEcCtD
Galantamine—BCHE—digestive system—esophageal cancer	0.00292	0.00968	CbGeAlD
Galantamine—Melaena—Capecitabine—esophageal cancer	0.00289	0.00711	CcSEcCtD
Galantamine—Urinary incontinence—Capecitabine—esophageal cancer	0.00286	0.00703	CcSEcCtD
Galantamine—Dehydration—Cisplatin—esophageal cancer	0.00271	0.00667	CcSEcCtD
Galantamine—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00266	0.00655	CcSEcCtD
Galantamine—Hypokalaemia—Cisplatin—esophageal cancer	0.00265	0.00653	CcSEcCtD
Galantamine—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00247	0.00608	CcSEcCtD
Galantamine—BCHE—lung—esophageal cancer	0.00244	0.00808	CbGeAlD
Galantamine—Gastroenteritis—Capecitabine—esophageal cancer	0.00243	0.00597	CcSEcCtD
Galantamine—Abdominal discomfort—Cisplatin—esophageal cancer	0.00242	0.00594	CcSEcCtD
Galantamine—Vascular purpura—Capecitabine—esophageal cancer	0.0024	0.00591	CcSEcCtD
Galantamine—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.00233	0.00573	CcSEcCtD
Galantamine—Atrial fibrillation—Capecitabine—esophageal cancer	0.00227	0.00558	CcSEcCtD
Galantamine—Renal impairment—Capecitabine—esophageal cancer	0.00226	0.00556	CcSEcCtD
Galantamine—Purpura—Capecitabine—esophageal cancer	0.00223	0.00549	CcSEcCtD
Galantamine—Arthritis—Capecitabine—esophageal cancer	0.00221	0.00544	CcSEcCtD
Galantamine—Renal failure—Cisplatin—esophageal cancer	0.00221	0.00543	CcSEcCtD
Galantamine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.0022	0.00542	CcSEcCtD
Galantamine—Cardiac failure—Capecitabine—esophageal cancer	0.0022	0.00542	CcSEcCtD
Galantamine—Lethargy—Capecitabine—esophageal cancer	0.00219	0.0054	CcSEcCtD
Galantamine—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00219	0.0054	CcSEcCtD
Galantamine—Melaena—Methotrexate—esophageal cancer	0.00215	0.0053	CcSEcCtD
Galantamine—Cystitis noninfective—Methotrexate—esophageal cancer	0.00215	0.0053	CcSEcCtD
Galantamine—Pain in extremity—Capecitabine—esophageal cancer	0.00215	0.00529	CcSEcCtD
Galantamine—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00213	0.00525	CcSEcCtD
Galantamine—Cystitis—Methotrexate—esophageal cancer	0.00213	0.00524	CcSEcCtD
Galantamine—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00213	0.00523	CcSEcCtD
Galantamine—Bradycardia—Cisplatin—esophageal cancer	0.00205	0.00505	CcSEcCtD
Galantamine—Urinary retention—Capecitabine—esophageal cancer	0.00204	0.00503	CcSEcCtD
Galantamine—Ataxia—Capecitabine—esophageal cancer	0.00202	0.00497	CcSEcCtD
Galantamine—Dehydration—Capecitabine—esophageal cancer	0.002	0.00492	CcSEcCtD
Galantamine—Bladder pain—Methotrexate—esophageal cancer	0.00199	0.0049	CcSEcCtD
Galantamine—Urinary tract disorder—Cisplatin—esophageal cancer	0.00199	0.0049	CcSEcCtD
Galantamine—Connective tissue disorder—Cisplatin—esophageal cancer	0.00198	0.00488	CcSEcCtD
Galantamine—Urethral disorder—Cisplatin—esophageal cancer	0.00198	0.00486	CcSEcCtD
Galantamine—CYP3A4—digestive system—esophageal cancer	0.00197	0.00652	CbGeAlD
Galantamine—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00196	0.00483	CcSEcCtD
Galantamine—Abdominal pain upper—Capecitabine—esophageal cancer	0.00196	0.00483	CcSEcCtD
Galantamine—Hypokalaemia—Capecitabine—esophageal cancer	0.00196	0.00481	CcSEcCtD
Galantamine—Visual impairment—Cisplatin—esophageal cancer	0.00194	0.00478	CcSEcCtD
Galantamine—CYP2D6—digestive system—esophageal cancer	0.00194	0.00641	CbGeAlD
Galantamine—Gastritis—Capecitabine—esophageal cancer	0.0019	0.00468	CcSEcCtD
Galantamine—Muscular weakness—Capecitabine—esophageal cancer	0.0019	0.00466	CcSEcCtD
Galantamine—Eye disorder—Cisplatin—esophageal cancer	0.00189	0.00464	CcSEcCtD
Galantamine—Tinnitus—Cisplatin—esophageal cancer	0.00188	0.00463	CcSEcCtD
Galantamine—Flushing—Cisplatin—esophageal cancer	0.00187	0.00461	CcSEcCtD
Galantamine—Cardiac disorder—Cisplatin—esophageal cancer	0.00187	0.00461	CcSEcCtD
Galantamine—Dysphagia—Capecitabine—esophageal cancer	0.00186	0.00457	CcSEcCtD
Galantamine—Immune system disorder—Cisplatin—esophageal cancer	0.00182	0.00448	CcSEcCtD
Galantamine—Arrhythmia—Cisplatin—esophageal cancer	0.0018	0.00443	CcSEcCtD
Galantamine—Bronchitis—Capecitabine—esophageal cancer	0.00179	0.00439	CcSEcCtD
Galantamine—Abdominal discomfort—Capecitabine—esophageal cancer	0.00178	0.00438	CcSEcCtD
Galantamine—Malnutrition—Cisplatin—esophageal cancer	0.00176	0.00432	CcSEcCtD
Galantamine—Flatulence—Cisplatin—esophageal cancer	0.00173	0.00426	CcSEcCtD
Galantamine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00173	0.00425	CcSEcCtD
Galantamine—Muscle spasms—Cisplatin—esophageal cancer	0.00169	0.00415	CcSEcCtD
Galantamine—Weight decreased—Capecitabine—esophageal cancer	0.00168	0.00413	CcSEcCtD
Galantamine—Hyperglycaemia—Capecitabine—esophageal cancer	0.00168	0.00412	CcSEcCtD
Galantamine—BCHE—lymph node—esophageal cancer	0.00167	0.00553	CbGeAlD
Galantamine—Pneumonia—Capecitabine—esophageal cancer	0.00167	0.0041	CcSEcCtD
Galantamine—Vision blurred—Cisplatin—esophageal cancer	0.00166	0.00407	CcSEcCtD
Galantamine—Depression—Capecitabine—esophageal cancer	0.00165	0.00406	CcSEcCtD
Galantamine—Tremor—Cisplatin—esophageal cancer	0.00165	0.00405	CcSEcCtD
Galantamine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00163	0.00402	CcSEcCtD
Galantamine—Lethargy—Methotrexate—esophageal cancer	0.00163	0.00402	CcSEcCtD
Galantamine—Ill-defined disorder—Cisplatin—esophageal cancer	0.00163	0.00401	CcSEcCtD
Galantamine—Renal failure—Capecitabine—esophageal cancer	0.00163	0.00401	CcSEcCtD
Galantamine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00162	0.00399	CcSEcCtD
Galantamine—Anaemia—Cisplatin—esophageal cancer	0.00162	0.00399	CcSEcCtD
Galantamine—Urinary tract infection—Capecitabine—esophageal cancer	0.00161	0.00396	CcSEcCtD
Galantamine—Malaise—Cisplatin—esophageal cancer	0.00158	0.0039	CcSEcCtD
Galantamine—Haematuria—Capecitabine—esophageal cancer	0.00158	0.00389	CcSEcCtD
Galantamine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00157	0.00385	CcSEcCtD
Galantamine—Epistaxis—Capecitabine—esophageal cancer	0.00156	0.00384	CcSEcCtD
Galantamine—Convulsion—Cisplatin—esophageal cancer	0.00152	0.00374	CcSEcCtD
Galantamine—Bradycardia—Capecitabine—esophageal cancer	0.00151	0.00372	CcSEcCtD
Galantamine—Ataxia—Methotrexate—esophageal cancer	0.0015	0.0037	CcSEcCtD
Galantamine—Myalgia—Cisplatin—esophageal cancer	0.0015	0.00368	CcSEcCtD
Galantamine—Haemoglobin—Capecitabine—esophageal cancer	0.00149	0.00368	CcSEcCtD
Galantamine—Rhinitis—Capecitabine—esophageal cancer	0.00149	0.00367	CcSEcCtD
Galantamine—Anxiety—Cisplatin—esophageal cancer	0.00149	0.00366	CcSEcCtD
Galantamine—Hepatitis—Capecitabine—esophageal cancer	0.00149	0.00366	CcSEcCtD
Galantamine—Haemorrhage—Capecitabine—esophageal cancer	0.00149	0.00366	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00148	0.00365	CcSEcCtD
Galantamine—Discomfort—Cisplatin—esophageal cancer	0.00148	0.00363	CcSEcCtD
Galantamine—Urinary tract disorder—Capecitabine—esophageal cancer	0.00147	0.00361	CcSEcCtD
Galantamine—Oedema peripheral—Capecitabine—esophageal cancer	0.00146	0.0036	CcSEcCtD
Galantamine—Connective tissue disorder—Capecitabine—esophageal cancer	0.00146	0.00359	CcSEcCtD
Galantamine—Urethral disorder—Capecitabine—esophageal cancer	0.00146	0.00359	CcSEcCtD
Galantamine—Visual impairment—Capecitabine—esophageal cancer	0.00143	0.00353	CcSEcCtD
Galantamine—Nervous system disorder—Cisplatin—esophageal cancer	0.00141	0.00346	CcSEcCtD
Galantamine—Thrombocytopenia—Cisplatin—esophageal cancer	0.0014	0.00345	CcSEcCtD
Galantamine—Tachycardia—Cisplatin—esophageal cancer	0.0014	0.00344	CcSEcCtD
Galantamine—Skin disorder—Cisplatin—esophageal cancer	0.00139	0.00342	CcSEcCtD
Galantamine—Eye disorder—Capecitabine—esophageal cancer	0.00139	0.00342	CcSEcCtD
Galantamine—Tinnitus—Capecitabine—esophageal cancer	0.00139	0.00341	CcSEcCtD
Galantamine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00139	0.00341	CcSEcCtD
Galantamine—Flushing—Capecitabine—esophageal cancer	0.00138	0.00339	CcSEcCtD
Galantamine—Cardiac disorder—Capecitabine—esophageal cancer	0.00138	0.00339	CcSEcCtD
Galantamine—Anorexia—Cisplatin—esophageal cancer	0.00137	0.00336	CcSEcCtD
Galantamine—Angiopathy—Capecitabine—esophageal cancer	0.00135	0.00332	CcSEcCtD
Galantamine—Immune system disorder—Capecitabine—esophageal cancer	0.00134	0.0033	CcSEcCtD
Galantamine—Hypotension—Cisplatin—esophageal cancer	0.00134	0.00329	CcSEcCtD
Galantamine—Arrhythmia—Capecitabine—esophageal cancer	0.00133	0.00327	CcSEcCtD
Galantamine—Abdominal discomfort—Methotrexate—esophageal cancer	0.00133	0.00326	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00131	0.00321	CcSEcCtD
Galantamine—Mental disorder—Capecitabine—esophageal cancer	0.0013	0.0032	CcSEcCtD
Galantamine—Malnutrition—Capecitabine—esophageal cancer	0.00129	0.00318	CcSEcCtD
Galantamine—Paraesthesia—Cisplatin—esophageal cancer	0.00129	0.00317	CcSEcCtD
Galantamine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00129	0.00316	CcSEcCtD
Galantamine—Flatulence—Capecitabine—esophageal cancer	0.00128	0.00314	CcSEcCtD
Galantamine—Dysgeusia—Capecitabine—esophageal cancer	0.00127	0.00312	CcSEcCtD
Galantamine—Back pain—Capecitabine—esophageal cancer	0.00125	0.00308	CcSEcCtD
Galantamine—Decreased appetite—Cisplatin—esophageal cancer	0.00125	0.00306	CcSEcCtD
Galantamine—Muscle spasms—Capecitabine—esophageal cancer	0.00124	0.00306	CcSEcCtD
Galantamine—Pneumonia—Methotrexate—esophageal cancer	0.00124	0.00305	CcSEcCtD
Galantamine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00124	0.00304	CcSEcCtD
Galantamine—Depression—Methotrexate—esophageal cancer	0.00123	0.00302	CcSEcCtD
Galantamine—Vision blurred—Capecitabine—esophageal cancer	0.00122	0.003	CcSEcCtD
Galantamine—Tremor—Capecitabine—esophageal cancer	0.00121	0.00298	CcSEcCtD
Galantamine—Renal failure—Methotrexate—esophageal cancer	0.00121	0.00298	CcSEcCtD
Galantamine—Ill-defined disorder—Capecitabine—esophageal cancer	0.0012	0.00295	CcSEcCtD
Galantamine—Anaemia—Capecitabine—esophageal cancer	0.0012	0.00294	CcSEcCtD
Galantamine—Feeling abnormal—Cisplatin—esophageal cancer	0.00118	0.00291	CcSEcCtD
Galantamine—Haematuria—Methotrexate—esophageal cancer	0.00118	0.00289	CcSEcCtD
Galantamine—Malaise—Capecitabine—esophageal cancer	0.00117	0.00287	CcSEcCtD
Galantamine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00117	0.00287	CcSEcCtD
Galantamine—Epistaxis—Methotrexate—esophageal cancer	0.00116	0.00286	CcSEcCtD
Galantamine—Vertigo—Capecitabine—esophageal cancer	0.00116	0.00286	CcSEcCtD
Galantamine—Syncope—Capecitabine—esophageal cancer	0.00116	0.00286	CcSEcCtD
Galantamine—Palpitations—Capecitabine—esophageal cancer	0.00114	0.00281	CcSEcCtD
Galantamine—Loss of consciousness—Capecitabine—esophageal cancer	0.00114	0.0028	CcSEcCtD
Galantamine—Body temperature increased—Cisplatin—esophageal cancer	0.00113	0.00279	CcSEcCtD
Galantamine—Cough—Capecitabine—esophageal cancer	0.00113	0.00278	CcSEcCtD
Galantamine—Hypertension—Capecitabine—esophageal cancer	0.00112	0.00275	CcSEcCtD
Galantamine—Haemoglobin—Methotrexate—esophageal cancer	0.00111	0.00274	CcSEcCtD
Galantamine—Haemorrhage—Methotrexate—esophageal cancer	0.00111	0.00272	CcSEcCtD
Galantamine—Hepatitis—Methotrexate—esophageal cancer	0.00111	0.00272	CcSEcCtD
Galantamine—Arthralgia—Capecitabine—esophageal cancer	0.0011	0.00271	CcSEcCtD
Galantamine—Myalgia—Capecitabine—esophageal cancer	0.0011	0.00271	CcSEcCtD
Galantamine—Chest pain—Capecitabine—esophageal cancer	0.0011	0.00271	CcSEcCtD
Galantamine—Anxiety—Capecitabine—esophageal cancer	0.0011	0.0027	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00109	0.00269	CcSEcCtD
Galantamine—Urinary tract disorder—Methotrexate—esophageal cancer	0.00109	0.00269	CcSEcCtD
Galantamine—Discomfort—Capecitabine—esophageal cancer	0.00109	0.00268	CcSEcCtD
Galantamine—Urethral disorder—Methotrexate—esophageal cancer	0.00109	0.00267	CcSEcCtD
Galantamine—Dry mouth—Capecitabine—esophageal cancer	0.00108	0.00265	CcSEcCtD
Galantamine—Visual impairment—Methotrexate—esophageal cancer	0.00107	0.00262	CcSEcCtD
Galantamine—Confusional state—Capecitabine—esophageal cancer	0.00107	0.00262	CcSEcCtD
Galantamine—Hypersensitivity—Cisplatin—esophageal cancer	0.00106	0.0026	CcSEcCtD
Galantamine—Shock—Capecitabine—esophageal cancer	0.00104	0.00256	CcSEcCtD
Galantamine—Nervous system disorder—Capecitabine—esophageal cancer	0.00104	0.00255	CcSEcCtD
Galantamine—Eye disorder—Methotrexate—esophageal cancer	0.00103	0.00254	CcSEcCtD
Galantamine—Thrombocytopenia—Capecitabine—esophageal cancer	0.00103	0.00254	CcSEcCtD
Galantamine—Tinnitus—Methotrexate—esophageal cancer	0.00103	0.00254	CcSEcCtD
Galantamine—Tachycardia—Capecitabine—esophageal cancer	0.00103	0.00254	CcSEcCtD
Galantamine—Asthenia—Cisplatin—esophageal cancer	0.00103	0.00253	CcSEcCtD
Galantamine—Cardiac disorder—Methotrexate—esophageal cancer	0.00103	0.00253	CcSEcCtD
Galantamine—Skin disorder—Capecitabine—esophageal cancer	0.00103	0.00252	CcSEcCtD
Galantamine—Hyperhidrosis—Capecitabine—esophageal cancer	0.00102	0.00251	CcSEcCtD
Galantamine—Anorexia—Capecitabine—esophageal cancer	0.00101	0.00248	CcSEcCtD
Galantamine—Angiopathy—Methotrexate—esophageal cancer	0.001	0.00247	CcSEcCtD
Galantamine—Immune system disorder—Methotrexate—esophageal cancer	0.001	0.00246	CcSEcCtD
Galantamine—Hypotension—Capecitabine—esophageal cancer	0.000987	0.00243	CcSEcCtD
Galantamine—Diarrhoea—Cisplatin—esophageal cancer	0.000981	0.00241	CcSEcCtD
Galantamine—Mental disorder—Methotrexate—esophageal cancer	0.00097	0.00239	CcSEcCtD
Galantamine—Malnutrition—Methotrexate—esophageal cancer	0.000964	0.00237	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000963	0.00237	CcSEcCtD
Galantamine—Insomnia—Capecitabine—esophageal cancer	0.000956	0.00235	CcSEcCtD
Galantamine—Paraesthesia—Capecitabine—esophageal cancer	0.000949	0.00233	CcSEcCtD
Galantamine—Dysgeusia—Methotrexate—esophageal cancer	0.000944	0.00232	CcSEcCtD
Galantamine—Back pain—Methotrexate—esophageal cancer	0.000932	0.00229	CcSEcCtD
Galantamine—Dyspepsia—Capecitabine—esophageal cancer	0.00093	0.00229	CcSEcCtD
Galantamine—Decreased appetite—Capecitabine—esophageal cancer	0.000918	0.00226	CcSEcCtD
Galantamine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000912	0.00224	CcSEcCtD
Galantamine—Vomiting—Cisplatin—esophageal cancer	0.000911	0.00224	CcSEcCtD
Galantamine—Fatigue—Capecitabine—esophageal cancer	0.000911	0.00224	CcSEcCtD
Galantamine—Vision blurred—Methotrexate—esophageal cancer	0.000908	0.00223	CcSEcCtD
Galantamine—Rash—Cisplatin—esophageal cancer	0.000904	0.00222	CcSEcCtD
Galantamine—Constipation—Capecitabine—esophageal cancer	0.000903	0.00222	CcSEcCtD
Galantamine—Dermatitis—Cisplatin—esophageal cancer	0.000903	0.00222	CcSEcCtD
Galantamine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000894	0.0022	CcSEcCtD
Galantamine—Anaemia—Methotrexate—esophageal cancer	0.000891	0.00219	CcSEcCtD
Galantamine—Feeling abnormal—Capecitabine—esophageal cancer	0.000871	0.00214	CcSEcCtD
Galantamine—Malaise—Methotrexate—esophageal cancer	0.000869	0.00214	CcSEcCtD
Galantamine—Vertigo—Methotrexate—esophageal cancer	0.000866	0.00213	CcSEcCtD
Galantamine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000864	0.00213	CcSEcCtD
Galantamine—Nausea—Cisplatin—esophageal cancer	0.000851	0.00209	CcSEcCtD
Galantamine—Cough—Methotrexate—esophageal cancer	0.000841	0.00207	CcSEcCtD
Galantamine—Abdominal pain—Capecitabine—esophageal cancer	0.000835	0.00205	CcSEcCtD
Galantamine—Body temperature increased—Capecitabine—esophageal cancer	0.000835	0.00205	CcSEcCtD
Galantamine—Convulsion—Methotrexate—esophageal cancer	0.000835	0.00205	CcSEcCtD
Galantamine—Arthralgia—Methotrexate—esophageal cancer	0.00082	0.00202	CcSEcCtD
Galantamine—Myalgia—Methotrexate—esophageal cancer	0.00082	0.00202	CcSEcCtD
Galantamine—Chest pain—Methotrexate—esophageal cancer	0.00082	0.00202	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000815	0.002	CcSEcCtD
Galantamine—Discomfort—Methotrexate—esophageal cancer	0.000811	0.00199	CcSEcCtD
Galantamine—Confusional state—Methotrexate—esophageal cancer	0.000793	0.00195	CcSEcCtD
Galantamine—Hypersensitivity—Capecitabine—esophageal cancer	0.000778	0.00191	CcSEcCtD
Galantamine—Nervous system disorder—Methotrexate—esophageal cancer	0.000771	0.0019	CcSEcCtD
Galantamine—Thrombocytopenia—Methotrexate—esophageal cancer	0.00077	0.00189	CcSEcCtD
Galantamine—Skin disorder—Methotrexate—esophageal cancer	0.000764	0.00188	CcSEcCtD
Galantamine—Hyperhidrosis—Methotrexate—esophageal cancer	0.00076	0.00187	CcSEcCtD
Galantamine—Asthenia—Capecitabine—esophageal cancer	0.000758	0.00186	CcSEcCtD
Galantamine—Anorexia—Methotrexate—esophageal cancer	0.00075	0.00184	CcSEcCtD
Galantamine—Hypotension—Methotrexate—esophageal cancer	0.000735	0.00181	CcSEcCtD
Galantamine—Diarrhoea—Capecitabine—esophageal cancer	0.000723	0.00178	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000717	0.00176	CcSEcCtD
Galantamine—Insomnia—Methotrexate—esophageal cancer	0.000711	0.00175	CcSEcCtD
Galantamine—Paraesthesia—Methotrexate—esophageal cancer	0.000706	0.00174	CcSEcCtD
Galantamine—Somnolence—Methotrexate—esophageal cancer	0.000699	0.00172	CcSEcCtD
Galantamine—Dizziness—Capecitabine—esophageal cancer	0.000699	0.00172	CcSEcCtD
Galantamine—Dyspepsia—Methotrexate—esophageal cancer	0.000692	0.0017	CcSEcCtD
Galantamine—Decreased appetite—Methotrexate—esophageal cancer	0.000684	0.00168	CcSEcCtD
Galantamine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000679	0.00167	CcSEcCtD
Galantamine—Fatigue—Methotrexate—esophageal cancer	0.000678	0.00167	CcSEcCtD
Galantamine—Vomiting—Capecitabine—esophageal cancer	0.000672	0.00165	CcSEcCtD
Galantamine—Rash—Capecitabine—esophageal cancer	0.000666	0.00164	CcSEcCtD
Galantamine—Dermatitis—Capecitabine—esophageal cancer	0.000666	0.00164	CcSEcCtD
Galantamine—Headache—Capecitabine—esophageal cancer	0.000662	0.00163	CcSEcCtD
Galantamine—Feeling abnormal—Methotrexate—esophageal cancer	0.000648	0.00159	CcSEcCtD
Galantamine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000643	0.00158	CcSEcCtD
Galantamine—Nausea—Capecitabine—esophageal cancer	0.000628	0.00154	CcSEcCtD
Galantamine—Body temperature increased—Methotrexate—esophageal cancer	0.000622	0.00153	CcSEcCtD
Galantamine—Abdominal pain—Methotrexate—esophageal cancer	0.000622	0.00153	CcSEcCtD
Galantamine—Hypersensitivity—Methotrexate—esophageal cancer	0.000579	0.00143	CcSEcCtD
Galantamine—Asthenia—Methotrexate—esophageal cancer	0.000564	0.00139	CcSEcCtD
Galantamine—Diarrhoea—Methotrexate—esophageal cancer	0.000538	0.00132	CcSEcCtD
Galantamine—Dizziness—Methotrexate—esophageal cancer	0.00052	0.00128	CcSEcCtD
Galantamine—Vomiting—Methotrexate—esophageal cancer	0.0005	0.00123	CcSEcCtD
Galantamine—Rash—Methotrexate—esophageal cancer	0.000496	0.00122	CcSEcCtD
Galantamine—Dermatitis—Methotrexate—esophageal cancer	0.000495	0.00122	CcSEcCtD
Galantamine—Headache—Methotrexate—esophageal cancer	0.000493	0.00121	CcSEcCtD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00047	0.00161	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—GNG7—esophageal cancer	0.000469	0.00161	CbGpPWpGaD
Galantamine—Nausea—Methotrexate—esophageal cancer	0.000467	0.00115	CcSEcCtD
Galantamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000467	0.0016	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000463	0.00159	CbGpPWpGaD
Galantamine—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000461	0.00158	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000452	0.00155	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000445	0.00153	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—ALDH2—esophageal cancer	0.000439	0.00151	CbGpPWpGaD
Galantamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000439	0.00151	CbGpPWpGaD
Galantamine—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000433	0.00149	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—EP300—esophageal cancer	0.000432	0.00148	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000431	0.00148	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—ADH7—esophageal cancer	0.000429	0.00147	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000422	0.00145	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—GNG7—esophageal cancer	0.000418	0.00143	CbGpPWpGaD
Galantamine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000416	0.00143	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000409	0.0014	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—EP300—esophageal cancer	0.000408	0.0014	CbGpPWpGaD
Galantamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000396	0.00136	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000394	0.00135	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—ALDH2—esophageal cancer	0.000392	0.00134	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000383	0.00132	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000379	0.0013	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000379	0.0013	CbGpPWpGaD
Galantamine—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000378	0.0013	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—ADH1B—esophageal cancer	0.000377	0.00129	CbGpPWpGaD
Galantamine—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000374	0.00128	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.000371	0.00127	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000371	0.00127	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000356	0.00122	CbGpPWpGaD
Galantamine—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000355	0.00122	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000351	0.00121	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.00035	0.0012	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—XBP1—esophageal cancer	0.000347	0.00119	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000345	0.00118	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000342	0.00117	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—SLC30A7—esophageal cancer	0.000333	0.00114	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000327	0.00112	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.000325	0.00112	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.000321	0.0011	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000319	0.0011	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—XBP1—esophageal cancer	0.00031	0.00106	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000307	0.00105	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000305	0.00105	CbGpPWpGaD
Galantamine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000301	0.00103	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—ST6GAL1—esophageal cancer	0.0003	0.00103	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—SLC30A7—esophageal cancer	0.000297	0.00102	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—TP53—esophageal cancer	0.000292	0.001	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000291	0.000999	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000287	0.000985	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000285	0.000978	CbGpPWpGaD
Galantamine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000283	0.000972	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000281	0.000963	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000279	0.000956	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000278	0.000956	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—ST6GAL1—esophageal cancer	0.000268	0.000918	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.000265	0.00091	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.000252	0.000866	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.000249	0.000856	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.000249	0.000855	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000249	0.000853	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.000248	0.000851	CbGpPWpGaD
Galantamine—ACHE—Metabolism—SLC52A3—esophageal cancer	0.000248	0.00085	CbGpPWpGaD
Galantamine—ACHE—Metabolism—BLVRB—esophageal cancer	0.000248	0.00085	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000247	0.000849	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000246	0.000845	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.000236	0.000811	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000233	0.000798	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000229	0.000785	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000226	0.000775	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000221	0.00076	CbGpPWpGaD
Galantamine—BCHE—Metabolism—SLC52A3—esophageal cancer	0.000221	0.000758	CbGpPWpGaD
Galantamine—BCHE—Metabolism—BLVRB—esophageal cancer	0.000221	0.000758	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	0.000214	0.000734	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000213	0.00073	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CA1—esophageal cancer	0.000211	0.000723	CbGpPWpGaD
Galantamine—ACHE—Metabolism—SLC10A2—esophageal cancer	0.000211	0.000723	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.00021	0.00072	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	0.000208	0.000713	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—ACTB—esophageal cancer	0.000207	0.000709	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	0.000203	0.000697	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000201	0.00069	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000198	0.00068	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000197	0.000678	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CA2—esophageal cancer	0.000193	0.000661	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000189	0.000649	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000188	0.000646	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CA1—esophageal cancer	0.000188	0.000645	CbGpPWpGaD
Galantamine—BCHE—Metabolism—SLC10A2—esophageal cancer	0.000188	0.000645	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—HSPA5—esophageal cancer	0.000187	0.000641	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000186	0.00064	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—ACTB—esophageal cancer	0.000184	0.000632	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	0.000184	0.00063	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—CALR—esophageal cancer	0.000181	0.000621	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ADH7—esophageal cancer	0.000179	0.000614	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PLCE1—esophageal cancer	0.000179	0.000614	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—GHRL—esophageal cancer	0.000178	0.00061	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	0.000178	0.000609	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000177	0.000607	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—FBXW7—esophageal cancer	0.000175	0.0006	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000173	0.000595	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CA2—esophageal cancer	0.000172	0.00059	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	0.000169	0.00058	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000168	0.000576	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—HSPA5—esophageal cancer	0.000167	0.000572	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000165	0.000566	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000163	0.00056	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—PIK3CA—esophageal cancer	0.000162	0.000556	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—CALR—esophageal cancer	0.000161	0.000554	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PLCE1—esophageal cancer	0.00016	0.000548	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ADH7—esophageal cancer	0.00016	0.000548	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—GHRL—esophageal cancer	0.000159	0.000544	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000158	0.000542	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ADH1B—esophageal cancer	0.000157	0.000539	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—FBXW7—esophageal cancer	0.000156	0.000536	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000155	0.000531	CbGpPWpGaD
Galantamine—ACHE—Metabolism—TYMP—esophageal cancer	0.00015	0.000515	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	0.000147	0.000505	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP26A1—esophageal cancer	0.000146	0.000501	CbGpPWpGaD
Galantamine—BCHE—Phospholipid metabolism—PIK3CA—esophageal cancer	0.000145	0.000496	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	0.000144	0.000494	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ALOX15—esophageal cancer	0.000142	0.000488	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ADH1B—esophageal cancer	0.00014	0.000481	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTO1—esophageal cancer	0.000136	0.000466	CbGpPWpGaD
Galantamine—ACHE—Metabolism—TPI1—esophageal cancer	0.000136	0.000466	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TYMP—esophageal cancer	0.000134	0.000459	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000131	0.000451	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP26A1—esophageal cancer	0.00013	0.000447	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ALDOB—esophageal cancer	0.00013	0.000446	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00013	0.000445	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ALOX15—esophageal cancer	0.000127	0.000435	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GAPDH—esophageal cancer	0.000125	0.00043	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	0.000125	0.000429	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CRABP1—esophageal cancer	0.000124	0.000426	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000124	0.000424	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000122	0.000418	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTO1—esophageal cancer	0.000121	0.000415	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TPI1—esophageal cancer	0.000121	0.000415	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	0.000121	0.000415	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GNG7—esophageal cancer	0.000118	0.000405	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ALDOB—esophageal cancer	0.000116	0.000398	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GAPDH—esophageal cancer	0.000112	0.000383	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CRABP1—esophageal cancer	0.000111	0.00038	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ALDH2—esophageal cancer	0.000111	0.00038	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GNG7—esophageal cancer	0.000105	0.000361	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTT1—esophageal cancer	0.000105	0.000361	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP2A6—esophageal cancer	0.000104	0.000357	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000104	0.000355	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000102	0.000349	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000102	0.000349	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ALDH2—esophageal cancer	9.87e-05	0.000339	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ENO1—esophageal cancer	9.86e-05	0.000338	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PTGS1—esophageal cancer	9.86e-05	0.000338	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PSME1—esophageal cancer	9.71e-05	0.000333	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PSME2—esophageal cancer	9.71e-05	0.000333	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTT1—esophageal cancer	9.39e-05	0.000322	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP2A6—esophageal cancer	9.28e-05	0.000318	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	9.24e-05	0.000317	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ENO1—esophageal cancer	8.8e-05	0.000302	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PTGS1—esophageal cancer	8.8e-05	0.000302	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PSME1—esophageal cancer	8.67e-05	0.000297	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PSME2—esophageal cancer	8.67e-05	0.000297	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CA1—esophageal cancer	8.64e-05	0.000296	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SLC10A2—esophageal cancer	8.64e-05	0.000296	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.48e-05	0.000291	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP1B1—esophageal cancer	8.38e-05	0.000288	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CA2—esophageal cancer	7.9e-05	0.000271	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP19A1—esophageal cancer	7.88e-05	0.00027	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.57e-05	0.00026	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP1B1—esophageal cancer	7.48e-05	0.000257	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PLCE1—esophageal cancer	7.34e-05	0.000252	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ADH7—esophageal cancer	7.34e-05	0.000252	CbGpPWpGaD
Galantamine—ACHE—Metabolism—HMOX1—esophageal cancer	7.19e-05	0.000247	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.06e-05	0.000242	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP19A1—esophageal cancer	7.03e-05	0.000241	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ABCB1—esophageal cancer	6.9e-05	0.000237	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SLC52A3—esophageal cancer	6.64e-05	0.000228	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—BLVRB—esophageal cancer	6.64e-05	0.000228	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ADH1B—esophageal cancer	6.44e-05	0.000221	CbGpPWpGaD
Galantamine—BCHE—Metabolism—HMOX1—esophageal cancer	6.42e-05	0.00022	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.29e-05	0.000216	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ABCB1—esophageal cancer	6.16e-05	0.000211	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TYMP—esophageal cancer	6.15e-05	0.000211	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	5.99e-05	0.000205	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ALOX15—esophageal cancer	5.83e-05	0.0002	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CA1—esophageal cancer	5.65e-05	0.000194	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	5.65e-05	0.000194	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTO1—esophageal cancer	5.57e-05	0.000191	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TPI1—esophageal cancer	5.57e-05	0.000191	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ALDOB—esophageal cancer	5.34e-05	0.000183	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.22e-05	0.000179	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CA2—esophageal cancer	5.16e-05	0.000177	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GAPDH—esophageal cancer	5.14e-05	0.000176	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CRABP1—esophageal cancer	5.09e-05	0.000175	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GNG7—esophageal cancer	4.84e-05	0.000166	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ADH7—esophageal cancer	4.8e-05	0.000165	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PLCE1—esophageal cancer	4.8e-05	0.000165	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.66e-05	0.00016	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CREBBP—esophageal cancer	4.61e-05	0.000158	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ALDH2—esophageal cancer	4.54e-05	0.000156	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTT1—esophageal cancer	4.32e-05	0.000148	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	4.27e-05	0.000146	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ADH1B—esophageal cancer	4.21e-05	0.000144	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NOS3—esophageal cancer	4.13e-05	0.000142	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CREBBP—esophageal cancer	4.12e-05	0.000141	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PTGS1—esophageal cancer	4.04e-05	0.000139	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ENO1—esophageal cancer	4.04e-05	0.000139	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TYMP—esophageal cancer	4.02e-05	0.000138	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PSME1—esophageal cancer	3.98e-05	0.000137	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PSME2—esophageal cancer	3.98e-05	0.000137	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	3.91e-05	0.000134	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ALOX15—esophageal cancer	3.81e-05	0.000131	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PTGS2—esophageal cancer	3.78e-05	0.00013	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NOS3—esophageal cancer	3.69e-05	0.000126	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTO1—esophageal cancer	3.64e-05	0.000125	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TPI1—esophageal cancer	3.64e-05	0.000125	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ALDOB—esophageal cancer	3.49e-05	0.00012	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	3.44e-05	0.000118	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PTGS2—esophageal cancer	3.37e-05	0.000116	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GAPDH—esophageal cancer	3.36e-05	0.000115	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CRABP1—esophageal cancer	3.33e-05	0.000114	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	3.23e-05	0.000111	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GNG7—esophageal cancer	3.17e-05	0.000109	CbGpPWpGaD
Galantamine—ACHE—Metabolism—EP300—esophageal cancer	3.14e-05	0.000108	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.97e-05	0.000102	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—HMOX1—esophageal cancer	2.95e-05	0.000101	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ABCB1—esophageal cancer	2.83e-05	9.72e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.82e-05	9.68e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—EP300—esophageal cancer	2.8e-05	9.62e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	2.79e-05	9.57e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ENO1—esophageal cancer	2.64e-05	9.07e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.64e-05	9.07e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PSME1—esophageal cancer	2.61e-05	8.94e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PSME2—esophageal cancer	2.61e-05	8.94e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PIK3CA—esophageal cancer	2.32e-05	7.98e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.25e-05	7.71e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	2.11e-05	7.25e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PIK3CA—esophageal cancer	2.07e-05	7.12e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.93e-05	6.62e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.89e-05	6.49e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.85e-05	6.35e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NOS3—esophageal cancer	1.69e-05	5.81e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PTGS2—esophageal cancer	1.55e-05	5.32e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—EP300—esophageal cancer	1.29e-05	4.42e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.24e-05	4.25e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NOS3—esophageal cancer	1.11e-05	3.8e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.01e-05	3.48e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	9.53e-06	3.27e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—EP300—esophageal cancer	8.43e-06	2.89e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	6.23e-06	2.14e-05	CbGpPWpGaD
